名称 | Dapagliflozin ((2S)-1,2-propanediol, hydrate) |
描述 | Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2), in development for treating type 2 diabetes mellitus (T2DM). It inhibits SGLT2, responsible for at least 90% of glucose reabsorption in the kidney. |
体外活性 | Dapagliflozin (2S)-1,2-propanediol, hydrate is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin inhibits sodium/glucose cotransporter 2 (SGLT2), which results in excretion of glucose into the urine. |
存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 50 mg/mL (99.41 mM)
|
关键字 | Dapagliflozin ((2S) 1,2 propanediol, hydrate) | inhibit | Inhibitor | Dapagliflozin propanediol Monohydrate | Dapagliflozin propanediol | Sodium-dependent glucose cotransporters | SGLT | BMS-512148 1,2-propanediol, Hydrate | Dapagliflozin ((2S)1,2propanediol, hydrate) | Dapagliflozin (1,2-propanediol, hydrate) |
相关产品 | Ertugliflozin L-pyroglutamic acid | Dapagliflozin | Ipragliflozin | Sotagliflozin | Phlorizin | Phloretin | Sergliflozin A | Empagliflozin | Canagliflozin | Ertugliflozin |
相关库 | 经典已知活性库 | 膜蛋白靶向化合物库 | EMA 上市药物库 | 药物功能重定位化合物库 | 抑制剂库 | FDA 上市药物库 | 抗癌上市药物库 | 已知活性化合物库 | GPCR靶点分子库 | 抗癌药物库 |